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Understanding How Map Kinases Influence Endothelial Nitric-Oxide Synthase Activity

ABSTRACT

Mitogen activated protein kinases (MAPK) p38 and ERK have both been reported to bind
endothelial nitric oxide synthase (eNOS) with submicromolar affinity via proposed interactions
with a pentabasic non-canonical MAPK binding sequence in the autoinhibitory insertion of eNOS.
The neuronal isoform, which lacks the pentabasic motif, did not bind either MAPK significantly.
In the present study, the pentabasic motif was validated using predictive modeling programming,
and eNOS phosphorylation by MAPKs (P38, ERK and JNK) was examined using in vitro kinase
assays and immunoblotting. JNK phosphorylation at Ser114 contrasts with ERK, which
phosphorylated Ser600, and p38, which phosphorylated both sites. Literature reports showed that
JNK1/2 activation does not alter eNOS activity and prior work in our lab showed that ERK
phosphorylation negativity affects NO output. This thesis presents in vitro results comparing the
direct impact of each kinase on eNOS activity using the oxyhemoglobin (Oxy-Hb) assay. In
HMEC-1 cells and in vitro it is observe that phosphorylation at these MAPK sites happens
concurrently with activating sites (Ser1177), creating dually phosphorylated eNOS. These results
underscore the importance of MAPK interactions with eNOS showing that each MAPK creates a
unique phosphorylation pattern and NO production outcome. These findings strengthen the
emerging paradigm of eNOS as a junction of multiple signaling pathways.

Keywords: eNOS, MAP Kinases, nitric oxide synthase, phosphorylation, nitric-oxide

iii

TABLE OF CONTENTS
Dedication ..................................................................................................................ii
Abstract ......................................................................................................................iii
Table of Contents .......................................................................................................iv
List of Figures & Tables ............................................................................................vi
Chapter 1: Literature Review ................................................................................1
Significance of Research

1

The Discovery of Nitric-Oxide as a Signaling Molecule

2

Nitric-Oxide Synthases

3

Endothelial Nitric-Oxide Synthase

5

Kinase Regulation of eNOS

6

Hypothesis and Specific Aims ...................................................................................11
Chapter 2: MAP Kinases Recognition Sequences in Human eNOS ...................12
Introduction

12

Experimental Procedures

13

Results

15

Discussion

17

Chapter 3: Understanding how MAP Kinases effect eNOS Activity through
Differential Phosphorylation ...............................................................19
Introduction

19

Experimental Procedures

21

Results

25

Discussion

27

Chapter 4: eNOS is Modified in Cells through Multiple Signaling Outputs .....31
Introduction

31

Experimental Procedures

32

Results

34

Discussion

35

Chapter 5: Conclusions, Future Directions, Integrative Statement, and
Acknowledgments .................................................................................37
Integrative Statement

38
iv

Acknowledgments

39

References ..................................................................................................................40
Supplementary Data ...................................................................................................47

v

LIST OF FIGURES AND TABLES
LIST OF FIGURES
1. Pathways involved in the synthesis of nitric oxide ..............................................2
2. Schematic overview of NOS structure .................................................................4
3. Sequence alignments of the zinc-binding motif...................................................5
4. Schematic overview of MAPK pathways ............................................................8
5. Graphical Hypothesis ...........................................................................................11
6. NOS multiple sequence alignment.......................................................................14
7. NOS modeling cartoon depicting nitric-oxide synthase ......................................16
8. Measurement of the distances between kinases ...................................................17
9. Schematic representation of hemoglobin species ................................................20
10. Purified eNOS absorbance spectrum from Hi Control ........................................26
11. MAP kinase differently phosphorylates eNOS ....................................................27
12. ERK inhibits eNOS activity while JNK does not ................................................28
13. ERK and P38 do not significantly alter the activity of eNOS .............................28
14. Bovine endothelial nitric-oxide synthase .............................................................30
15. Graphical representation of dually phosphorylated eNOS ..................................31
16. ERK binds differentially phosphorylated eNOS..................................................34
17. eNOS is phosphorylated through multiple signaling outputs ..............................35

LIST OF TABLES
1. eNOS phosphorylation sites and kinases .............................................................7
2. A list of measurements between the kinases docking site ...................................18
3. Buffers used for the purification of eNOS ...........................................................22
4. NOS isolated from diverse species .....................................................................47
vi

Chapter 1: Literature Review
SIGNIFICANCE OF RESEARCH
Cardiovascular Disease
According to The Center for Disease Control and Prevention (CDC), approximately 90
million people have known cardiovascular disease. Of these, 800,000 people have heart attacks
and over 500,000 people die from heart disease every year (1, 2). One cardiovascular disease is
atherosclerosis, the hardening and narrowing of arteries. Usually, atherosclerosis is asymptomatic.
However, by the time the disease becomes symptomatic, the arteries have constricted to the point
of creating a life-threatening situation.
Type 2 Diabetes Mellitus
In 2015, the American Diabetes Association (ADA) reported that more than 30 million
Americans have been diagnosed with diabetes; this is approximately 9% of the population. The
CDC states that Type-2 Diabetes Mellitus (T2DM) accounts for 90 to 95 percent of all diagnosed
cases (3). T2DM results from the loss or dampened function of beta-cells to secrete enough insulin
to maintain normal blood glucose levels. This results in cellular insulin resistance via
hyperinsulinemia (increased insulin secretion due to hyperglycemia; increased blood glucose).
People who are insulin resistant undergo phenotypic changes that result in glucose abnormalities
such as impaired trafficking of glucose into peripheral tissue (4). Normally, glucose enters the
blood-stream via the liver and digestive system; the pancreas secretes insulin which is then
recruited to the insulin receptor; promoting glucose uptake into tissues (4).
Link between Diseases
Investigating both of these diseases has revealed many overlapping pathways between
T2DM and cardiovascular disease. Our work is focused on a molecule implicated in both
pathways, Nitric Oxide (NO). NO is a gaseous small molecule that signals and effects an array of
physiological processes. Changes in NO production are involved in the progression of
atherosclerosis (5–10). T2DM patients have also been shown to have decreased levels of detectable
NO and are not able to secrete sufficient insulin in response to hyperglycemia and this contributes
to the development of insulin resistance. While it is known that NO plays a role in the development
of insulin resistance (11, 12), the capacity and the molecular mechanism in which NO regulates
inulin resistance remain unknown.
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THE DISCOVERY OF NITRIC-OXIDE AS A SIGNALING MOLECULE
NO diffuses extracellularly, targets smooth muscles cells, blood platelets, and affects an
array of physiological processes, including mitochondrial biosynthesis, neurotransmission, blood
pressure regulation, smooth muscle relaxation, and immune function (13–17). In the late 1970s,
NO was known as a common air pollutant formed through the burning of nitrogen and biologically
thought to be another ligand that could activate guanylate cyclase. However, in the 1980s, NO was
appreciated as a critical endogenous vasorelaxant molecule.
The work of the Robert F. Furchgott, Louis J. Ignarro, and Ferid Murad labs changed our

Figure 1: Pathways involved in the synthesis of nitric oxide and the downstream physiological
effects of the gas.

NO3 - nitrate, NO2 - nitrite, NOS - nitric-oxide synthase. NO signals a number of
physiological responses such as angiogenesis, inflammation, and vasodilation leading to the
regulation of blood pressure, muscular relaxation, and vascular remodeling. Lower NO
production and increased NO inactivation are major factors that contribute to the increase of
endothelial dysfunction –adopted from (83)
understanding of NO.
Their work demonstrated that endothelial derived relaxation factor (EDRF) was in fact NO
and that this gas could function as a signaling molecule in the cardiovascular system. Further work
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revealed that nitroglycerin and other vasodilatory molecules release NO, which enables relaxation
of smooth muscle cells (18, 19). As a result of their work, it is now understood how an unstable
molecule like NO with a biological half-life of 10 seconds functions as an important signaling
molecule in the cardiovascular system.

Nitric-Oxide Promotes Angiogenesis and Cell Migration
Endothelium-derived NO was found to be necessary for the promotion of angiogenesis
signaled by the release of vascular endothelial growth factor (VEGF) (20–22). However, NOmediated angiogenesis has not been fully elucidated. It is known that NO works to inhibit apoptosis
and promotes endothelial cell survival and proliferation through the expression of VEGF (22).
Furthermore, NO promotes endothelial migration through the stimulation of endothelial cell
podokinesis, best defined as the scalar control of micromotion to vectorial movement (22–24). Nnitro-L-arginine methyl ester (L-NAME) is a competitive inhibitor of NO synthesis and suppresses
endothelial cell migration in human umbilical vascular endothelial cells (HUVEC) (23). Taken
together, these findings show that endothelium-derived NO is important for endothelial cell
survival, migrations, and angiogenesis.
NITRIC-OXIDE SYNTHASES
Nitric-Oxide Synthases (NOS) are a family of enzymes that catalyze the production of
nitric-oxide (NO) from L-arginine; there are three main isoforms indicative of where they were
discovered. NOS I (iNOS; inducible/immune nitric-oxide synthase), NOS II (nNOS; neuronal
nitric-oxide synthase), and NOS III (eNOS; endothelial nitric-oxide synthase). All isoforms of
NOS use L-arginine, molecular oxygen (O2), and nicotinamide-adenine-dinucleotide phosphate
(NADPH) as co-substrates. All have a heme prosthetic group, and all use flavin adenine
dinucleotide (FAD), flavin mononucleotide (FMN), and (6R-)5,6,7,8-tetrahydro-L-biopterin
(BH4) as cofactors (25). NOS isoforms exist as homodimers and cannot produce NO unless
dimerized (26, 27).
In order for NOS to produce NO the guanidine nitrogen of L-arginine is hydrolyzed to an
N-hydroxy-L-arginine (NOHA) intermediate; NOHA is further oxidized by NOS to form NO and
L-citrulline (28). The balanced reaction for the production of NO is 2 L-arginine + 3 NADPH + 3 H+ +
4 O2 ⇋ 2 citrulline + 2 NO + 4 H2O + 3 NADP+. Simply put eNOS consumes 1 mole of L-arginine, 1.5
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moles of NADPH, and 2 moles of oxygen to produce NO. The catabolic reaction described can be
altered through a number of mechanisms including direct protein interactions and posttranslational modifications. The binding of NADPH to NOS initiates the transfer of electrons
through the flavin molecules to the heme complex and allows for heme to bind and activate
molecular oxygen for NO production (Figure 2). However, without calmodulin (CaM) binding
NOS is rendered inactive because the reductase domain cannot coordinate with the oxygenase
domain (29, 30). CaM is a ubiquitously expressed small Ca2+ binding protein that enhances the
rate of electron transfer from NADPH to the flavin molecules and ultimately the heme complex
and was the first protein shown to interact with NOS (28). Furthermore, CaM functions as a
coordinator of both the oxygenase and reductase domain, for all three NOSs.
Interdomain Electron Transfer, Dimerization, and eNOS Catalysis
NOSs evolutionarily have similar protein structures characterized by an N-terminal
catalytic heme-containing oxygenase domain (NOSoxy) and a C-terminal flavin-containing
reductase domain (NOSred). NOSoxy contains binding sites for a zinc tetrathiolate and heme
center. (6R)-5,6,7,8-tetrahydrobiopterin (BH4) and L-arginine are linked by a CaM-recognition
site to NOSred which contains binding sites for flavin adenine dinucleotide (FAD), flavin

Figure 2: Schematic overview of NOS structure
The oxygenase domain (N-terminal) and a reductase domain (C-terminal) separated by a
calmodulin binding domain. The reductase domain binds NADPH and contains binding sites
for FMN and FAD. The oxygenase domain contains binding sites for BH4 and heme and also
binds L-arginine. Note: Electrons are transferred from the NADPH donor via FMN and FAD
through the reductase domain to the oxygenase domain of the adjacent monomer (not shown).
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mononucleotide (FMN), and NADPH. NOSoxy and NOSred are connected by a CaM binding
linker sequence that catalyzes the flow of electrons from the NADPH donor through NOSoxy to
the heme center, where molecular oxygen is bound and activated. All the isoforms have this linker,
but iNOS is unique in that CaM binding is Ca2+ independent, while it is a Ca2+ dependent event
for eNOS and nNOS. Additionally, NOS is only able to produce NO as a homodimer (fully
coupled) interfacing through the heme domains. Under this condition, NO production requires 1.5
NADPH molecules per NO molecule; any deviation from this results in uncoupled eNOS and the
production of alternate reactive oxygen
species (ROS) such as superoxide. Another
difference that eNOS and nNOS have from
iNOS is the insertion of an auto-inhibitory
loop (AI insertion). The AI insertion is a
flexible 37 amino acid sequence that is often
embedded within the structure (not exposed to
the protein surface). The AI insertion contains
a conserved helical region that essentially
stabilizes

eNOS/nNOS

and

prevents

conformational changes necessary for the
catalytic cycle and will be discussed further
within the thesis.
The dimer interface involves a large

Figure 3: Sequence Alignments of the ZincBinding Motif
Conservation among NOS cysteines that
coordinate the zinc ligand. Within the Cys(X)4-Cys motif the (X) 4 appears to prefer
hydroxylated (Ser and Thr) and charged (Arg,
His, and Lys) residues. Modified from (37).

portion of the NOSoxy domain; this interface
involves the binding site for BH4 and structures the “active site” pocket for heme and L-arginine
incorporation. Furthermore, eNOS contains an N-terminal beta-hairpin hook that stabilizes
dimerization (61aa-106aa in bovine eNOS) by exchanging “switching” between the two
monomers. The “switching” mechanism is thought to be only for stabilization purposes, as
heterodimers of both full-length NOS and hook-defective mutants were active in almost all cases
(27, 31). The N-terminal hook region primarily interacts with its own subunit in the unswapped
conformation and crosses to associate with the opposite subunit in the swapped conformation (27).
Catalysis of all three NOS isoforms depend on the cofactor BH4; binding of BH4 causes
the heme center to shift to its high-spin state (maximum peak at 400nm (32)). BH4 is a key
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regulator of NOS, functioning as an allosteric regulator for L-arginine binding (31, 33, 34). BH4
binding causes a conformational change in NOS that increases eNOS affinity for arginine-based
ligand binding (35, 36). BH4 is further stabilized through zinc coordination with Cys96 and Cys101.
Evolutionary, NOS contains this Cys-(X)4-Cys motif (Figure 3) allowing zinc to form a zinctetrathiolate between the two monomers (27, 37, 38). The (Xs) are usually hydroxylated and
charged residues. The zinc ligand is critical for eNOS dimerization in vivo; if zinc were missing
the reducing conditions of the cytosol would prevent the cysteine sulfhydryl coordination (37). In
other words, weak zinc coordination results in eNOS deterioration and subsequently less NO
synthesis.
ENDOTHELIAL NITRIC-OXIDE SYNTHASE
Endothelial Nitric-Oxide Synthase functions as a major vasoprotective protein due in large
part because it is expressed at high levels in vascular endothelial cells. Interestingly, eNOS has a
number of unique means of regulation. For example, eNOS is co-translated with a myristoyl group
covalently attached to the glycine residue in the first amino acid position (the met residue is cleaved
off in the process of myristoylation (39). This allows eNOS to localize to specialized plasmamonal
invaginations coined caveolae and stay in close proximity with other factors that negatively
regulate its function (34). eNOS can also localize to other regions in the membrane that allow for
positive regulation. Research suggests that myristoylation is a requirement of membrane
localization and eNOS yields maximum activity at the membrane (40). Another study suggested
that myristoylation targets eNOS to the Golgi complex (41), where eNOS is post-translationally
modified by palmitoylation at cysteine residues 15 and 25 to allow for the tighter anchorage at the
Golgi membrane (26). Myristoylation is required before palmitoylation can occur; through
palmitoylation modifications are reversible. Studies suggest that palmitoylation may help stabilize
eNOS and is required for localization (42). eNOS localized to caveolae generally associates with
caveolin 1 (43).
KINASE REGULATION OF ENOS
eNOS Regulation by Phosphorylation
eNOS plays a critical role in maintaining vascular integrity via the enzymatic generation
of NO. The enzyme is regulated by phosphorylation at tyrosine (Tyr), threonine (Thr), and serine
(Ser) residues (Table 1). One study shows that hyperphosphorylation in response to agonists and
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shear stress promotes activating
and inhibitory alterations in NO
generation (44). Of these sites,
known activation sites include
Ser615, Ser633, and Ser1177. Known
inhibitory sites include Tyr83,
Ser114, Ser600, Thr495, and Tyr657
(45, 46). A number of residues are

Table 1: eNOS phosphorylation sites and kinases
Phosphorylation
Effect on
Kinases
Sites
eNOS Activity
Tyrosine 87
Increases
SRC
Serine 114
Decreases?
JNK/P38
Threonine 495
Decreases
PKC
Serine 600
Decreases?
ERK/P38
Serine 615
Increases
PKA/AKT
Serine 633
Increases
PKA
Serine 1177
Increases
PKA/AKT/CaMKII

targeted by the phosphatidylinositol-3 kinase (PI-3K) pathway; which activates the downstream
kinase AKT, which in turn phosphorylates eNOS. Increased intracellular calcium levels activate
CaM and sequentially CaM kinase II activation and Ser1177 phosphorylation. Studies show that
phosphorylation of Ser1177 renders the enzyme more responsive to much lower levels of calcium
(47). Furthermore, eNOS phosphorylation by mitogen-activated-protein kinase (MAPK) dampens
NO generation and causes endothelial dysfunctional such as T2DM (48).

Mitogen-Activated Protein Kinases
Mitogen-activated Protein Kinases or MAP kinases are serine/threonine kinases that
transmit extracellular signals into a wide range of intracellular responses. Highly conserved among
Eukaryotes, MAPKs participate in the most ancient signal transduction pathways and are widely
used throughout evolution in many physiological processes (49). Activation of MAP kinases cause
phosphorylation of a variety of intracellular targets including transcription factors, transcriptional
adaptor proteins, membrane and cytoplasmic substrates, and other protein kinases and will
ultimately lead to physiological functions including growth, cell division, apoptosis, development,
metabolism, proliferation, diabetes, cancer, angiogenesis, and others.
Conventional MAPKs follows a classical three-tiered kinase cascade; MAPKK kinase
(MAPKKK), to MAPK kinase (MAPKK), to MAP kinase. Currently there are fourteen
MAPKKKs, (Raf-1, A-Raf, B-Raf, Mos, TAK1, MUK, SPRK, MST, MEKK 1-4, Tpl-2, and ASK)
seven MAKKs, (MEK1&2, MKK3-7) and 12 MAP Kinase (c-JUN amino (N)-terminal kinases
(JNK1/2/3), p38 (), and ERK1-5) (Figure 4). This work focuses on how MAP Kinases
(P38, ERK, and JNK) regulate eNOS.
7

Figure 4: Schematic overview of MAPK pathways
MAP Kinases shuttle between the cytoplasm and the nucleus, catalyze the phosphorylation of
dozens of cytosolic proteins and numerous nuclear transcription factors impacting many
cellular processes. See text for details -adapted and modified from (84) .
Extracellular Signal Regulated Protein Kinase
Extracellular-signal-regulated kinase (ERK) is stimulated by growth factors and mitogens.
This promotes a downstream activation cascade and leads to the phosphorylation and activation of
ERK to carry out physiological processes such as cellular growth, proliferation, and differentiation.
Our lab determined that ERK phosphorylates eNOS at Ser600 and hypothesized that it caused a
conformational change in eNOS structure, which resulted in decreased NO generation (46).
Furthermore, mass spectrometry identified three sites of ERK phosphorylation in vitro: Thr46,
Ser58, and Ser600.
ERK binds with high affinity and phosphorylates endothelial nitric-oxide synthase (eNOS)
(46, 50). However, controversy exists regarding the modulation of eNOS through the MAP kinase
pathway. Some studies report that ERK enhances NO synthesis through increased eNOS
expression (51, 52) while others report inhibition (34, 46) of eNOS activity through
phosphorylation. Most of the confusion stems from reports about which sites on eNOS are
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phosphorylated by ERK (53). Our lab and other groups have shown that ERK interacts with eNOS
(46, 50, 53); i.e. in cells ERK is released from eNOS in response to bradykinin stimulation and
later re-complexes (53).
c-Jun N-terminal kinase
c-Jun N-terminal kinase (JNK) is stimulated by stressors such as hyper-osmosis, oxidative
stress, and inflammatory cytokines (see figure 4). These stimuli promote the activation of
downstream kinases, ultimately leading to the phosphorylation and activation of JNK. The JNK
pathway is implicated in a number of physiological responses including cellular cycle arrest,
apoptosis, inflammation, growth, and cellular differentiation. JNK was also shown to directly
phosphorylate eNOS at Ser114 altering its activity (54). In this study, a dominant negative of
JNK1/2 was introduced to BAEC cells. As expected, dn-JNK2 significantly increased basal NO;
increasing confidence that JNK1/2 phosphorylates eNOS in vitro and in situ (54). Furthermore,
JNK2 co-immunoprecipitated with eNOS from cell lysates and confocal microscopy reveals that
JNK1/2 appears to be co-localized in the cytosol of BAEC cells (54). Overall, these results suggest
that eNOS directly interacts with JNK1/2 and treatment with JNK inhibitor SP600125 increases
basal NO generated in BAE cells.
Protein Kinases AGC
MALDI-TOF mass spectrometry data suggests protein kinase A (PKA) phosphorylates
Ser615, Ser633 and Ser1177 while protein kinase B (AKT) phosphorylates only at Ser615 and Ser1177
(55). However, our lab has shown (in vitro) that both kinases can phosphorylate all three activating
sites. Cellular conditions such as sheer stress and serum induced activation of AKT have been
shown to increase eNOS-induced synthesis of NO through phosphorylation at Ser1177 and Ser615
respectively (26, 56). HUVEC exposed to shear stress for up to one hour resulted in the rapid (2fold increase) phosphorylation and subsequent activation of AKT.
Further experimentation showed that phosphomimetic S1177D mutants results in
significantly augmented eNOS enzymatic activity measured using the labeled L-citrulline assay
(56). In contrast, overexpression of the eNOS phospho-null construct S1177A prevented AKT
phosphorylation of eNOS at Ser1177 by sheer stress (56). Furthermore, it was thought that
phosphorylation at Ser1177 would increase NO synthesis independently of Ca2+ stimulation. As
expected, the results showed that stepwise decreases in CaCl2+ resulted in stepwise decreases in
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wild-type eNOS activity. However, the phosphomimetic S1177D remained active despite
alterations Ca2+ stimulation. Together these results show that shear stress-induced phosphorylation
of eNOS by AKT enhances enzyme activity in a Ca2+ dependent manner (56).
eNOS phosphorylation at Thr495 by PKC results in decreased calmodulin binding,
decreased NO synthesis, and increased association with caveolin (57). These investigators
incubated BH4 free eNOS with and without AKT or PKC. AKT significantly increased superoxide
synthesis showing that phosphorylation at Ser615, Ser633, & Ser1177 also promotes activation of
uncoupled eNOS. Conversely, PKC-mediated phosphorylation also inhibited superoxide synthesis
via phosphorylation at Thr495 and shows that phosphorylation at Thr495 significantly inhibits eNOS
activity.
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Hypothesis and Specific Aims

This research aimed to understand the regulation of eNOS that occurs through MAP Kinases,
including protein-protein interactions and phosphorylation.

Figure 5: Graphical Hypothesis
PKA phosphorylates eNOS at Ser1177 increasing eNOS activity while we propose MAP
Kinases P38, JNK, and ERK phosphorylate eNOS at Ser600 and/or Ser114 and decreases eNOS
activity. However, we question how phosphorylation at Ser1177 congruently with
phosphorylation at Ser600/Ser114 affects eNOS activity.

The specific aims were:
1. To develop a model of human eNOS reductase and measure the distances between kinase
docking and phosphorylation sites.
2. To determine whether MAP Kinases differentially phosphorylate eNOS and whether this
alters NO synthesis rate.
3. To determine the physiological relevance of eNOS phosphorylation at Ser600.
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Chapter 2: MAP Kinases Recognition Sequences in Human eNOS
INTRODUCTION
Our lab has shown that both P38 and ERK2 bind to eNOS with high affinity whereas ERK
weakly binds nNOS and P38 does not bind nNOS (50). This work was followed by a closer
examination of how ERK binds, phosphorylates, and alters eNOS activity (46). ERKphosphorylated eNOS was sent for mass spectroscopy; that data identified three novel
phosphorylation sites (46), of which the Ser600 position was identified as an ideal regulatory site.
Ser600 falls within the eNOS autoinhibitory (AI) insertion. This region is homologous in eNOS and
nNOS however, only eNOS has a conserved pentabasic motif (627Arg-Arg-Lys-Arg-Lys631) within
the AI insertion. The pentabasic motif is homologous to known MAP kinase binding sequences,
so the lab hypothesized that this region could be responsible for the strong binding of MAP Kinases
to eNOS and not nNOS. Our lab proposed that ERK binds the pentabasic motif and phosphorylates
eNOS at Ser600. Though not fully tested, it was interpreted through experimentation using FMN
fluorescence lifetime imaging that phosphorylation at Ser600 by ERK was likely disrupting the flow
of electrons through the eNOS reductase domain and negatively impacting NO production.
Around the same time, another group suggested that the MAP Kinase JNK recognizes
another motif conserved in eNOS within the oxygenase domain (98P-Arg-Arg-CLGS-Leu-ValLeu-P108; PRRC motif) (54). Looking closely at the proposed PRRC motif it is also not well
conserved in nNOS and that led us to hypothesize that the MAP Kinases may differentially bind
eNOS. Together with phosphorylation data, it is hypothesized that ERK binds the pentabasic motif
preferentially and phosphorylates eNOS at Ser600. JNK is hypothesized to bind at the PRRC motif
and phosphorylate eNOS at Ser114, and P38 is hypothesized to bind and phosphorylate both sites.
Therefore, it was decided that utilizing bioinformatics and structural modeling techniques were
best to probe these hypotheses.
A literature search revealed the existence of a crystal structure of Arrestin 2 and MEK1 has
been shown to interact with Arrestin 2 (58). This served as a positive control for the distance
between the kinase docking site and the known phosphorylation site. MEK1 binds Arrestin2
at 26EFVE29 (58)

which

is

visible

in

the

crystal

structure;

phosphorylates Arrestin 2 at Ser412 which is not visible in the crystal.
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however,

MEK1

Bioinformatics and Computational Programs
There are currently no crystal structures of eNOS reductase domain. Therefore, designing
a model is necessary to test if the pentabasic motif is within an appropriate distance that would
allow MAP Kinases to mediated phosphorylation at nearby sites. UniProt (59), Jalview (60),
PROMALS3D (61), I-Tasser (62–64), and PyMOL (65) were used to design a model. UniProt is
a comprehensive protein database that pulls sequences from EMBL-Bank, GenBank, and DDBJ
nucleotide sequence resources. Jalview is a free editing and visualization analysis program.
PROMALS3D is a multiple sequence alignment (MSA) program that incorporates information
from crystal structures to create structurally-informed secondary structures MSAs. I-Tasser is an
online platform that generates quality predictive 3D models of protein structures. The servers
retrieve structures of similar sequences from the PDB to use as a template(s) for modeling.
Insertions in the query sequence are modeled ab initio. PyMOL is another visual analytic program,
mainly for the visualization of micro and macromolecules and is heavily used in structural biology.
The Py extends to the programing language Python.
Objective and Hypothesis
Our objective is to determine whether the distances between the putative MAP Kinases
recognition sequences – pentabasic motif or PRRC motif – and the respective phosphorylation
sites on eNOS are realistic, by comparing them to the distances between MEK binding and
phosphorylation sites in Arrestin2 (66).

EXPERIMENTAL PROCEDURES
Materials and Methods
Identifying NOS Isoforms for Creating a Multiple Sequence Alignment
Queries for various text strings – nitric oxide synthase endothelial, nitric oxide synthase
neuronal, and nitric oxide synthase inducible – were submitted to the UniProt database. The query
for nitric oxide synthase endothelial resulted in 163 peer-reviewed hits and was further filtered to
select sequences from diverse species including plants (tulips) and vertebrate (mammals such as
human, pigs, bovine and non-mammals such as fish, chickens, bats, and reptiles) and is shown in
supplementary table 1. For example, one eNOS sequence was added to our list by clicking
Eukaryota followed by Anthurium amnicola (tulip). The query search for nitric oxide synthase
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Figure 6: NOS Multiple sequence alignment
High quality NOS sequence alignment queried from diverse species. Residues are colored according to side
chain characteristics. The red arrow indicates the amino acid where human eNOS was truncated. The green
arrow depicts where crystal structure 1TLL 13 starts.
neuronal resulted in 137 reviewed hits and was further filtered to include sequences from diverse
species (mammals, plants, hydrozoans, and non-mammals) similar to the ones from the eNOS
query. The same process was used for the query nitric oxide synthase inducible (114 reviewed
hits) however, more fish were included for this selection as well as plants and vertebrates. Taken
together a total of 39 hits were selected from our query of eNOS 30 from nNOS and 34 from iNOS
queries and can be found in supplemental table 1. The selected NOS sequences were downloaded
as individual FASTA files, loaded into Jalview (60), and saved as a multi-FASTA file.
Designing a Structurally Informed Multiple Sequence Alignment of NOS
After a comprehensive literature search, crystal structures of rat nNOS reductase domain
(1TLL (67)), rat nNOS FAD/NADP+ domain (1F20 69), and the human iNOS reductase and
calmodulin complex (3HR4) were selected as crystal templates to include for structural
information with PROMALS3D. The NOS sequences selected from the database search were
submitted to the PROMALS3D webserver (61), specifying the three crystal structures use for
structural information; all other settings were default. After three days PROMALS3D returned a
structurally informed MSA which was visualized in Jalview (Figure 6) (60). This MSA and the
crystal structures were used to inform the decision to use position 492aa as the beginning of the
human eNOS (heNOS) reductase domain.
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heNOS Model Design and Verification
The reductase domain of heNOS was submitted to I-Tasser (62–64) with default settings.
Five models were returned along with the associated confident scores (C-score). To verify that the
model was conformationally correct 1TLL (67) was superimposed to the model using the align
tool in PyMOL (65). The alignment of the model with the crystal structure agreed with the MSA,
providing confidence in the model’s accuracy.
Determining Kinases Docking Sites to Phosphorylation Sites
The crystal structure of the MEK/Arrestin complex (2WTR) (66), the crystal structure of
the oxidase domain of bovine eNOS (1NSE (37)), and the homology model of the heNOS
reductase domain was visualized in PyMOL. The PyMol measurement tool was used to perform
the following measurements: in 2WTR (66), the distance between the alpha carbon Lys400 and the
alpha carbon of each amino acid of 26EFVE29; in 1NSE (37), the distance between Ser114 and
each amino acid of the LVL motif in the PRRC region 103LVL104; and in the homology model, the
distance between the alpha carbon of Ser600 and the alpha carbons of each amino acid in
627

RRKRK630.

RESULTS
Human eNOS Model Verification
To produce and evaluate the quality of the eNOS reductase domain homology model, multiple
NOS sequences from diverse species were aligned using the information provided from homologs
with 3D structures (1TLL, 1F20, 3HR4) (67–69), producing the secondary structure informed
MSA shown in figure 6. In order to model a 3D structure of human eNOS reductase domain, fulllength heNOS was first truncated to just the reductase domain (amino acids 492-1203) as shown
in figure 6. The reductase domain was submitted to I-Tasser (62–64) for modeling. ITasser returned 5 predicted models. Model 1 had the best confident score (-0.02), which was 10fold higher confidence than the next ranking model. To further evaluate Model 1 (Figure 7.a), it
was superimposed onto rat nNOS reductase domain crystal structure 1TLL (67). As expected,
Model 1 superimposes with low RMSD, 0.494 A onto 1TLL (67). One region of lower confidence
is the auto-inhibitory (AI) insertion which has not been crystallized. The AI insertion is based
on ab initio modeling. Still, 1TLL (67) has a partial a-helix that matches with the heNOS model’s
AI insertion, providing confidence in the general position of this insertion.
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A

B

Figure 7: NOS Modeling Cartoon Depicting Nitric-Oxide Synthase Reductase Domain
(A) eNOS model displaying the pentabasic region in blue. (B) eNOS model (gold)
superimposed to rat nNOS reductase domain (blue).

Measurements of the Distance between Kinases Docking Motif and Phosphorylation Site
In table 2 we show the calculated distances between each amino acid of the proposed
docking motif on the substrate to the proposed phosphorylation site. Figure 8a-c shows an example
of one measurement for each binding/phosphorylation pair. The positive control of Arrestin 2 and
MEK shows distances varying between 30.2 Å and 37.5 Å. ERK and P38 are proposed to bind
the pentabasic motif

and

phosphorylate eNOS at

Ser600.

The

distance

between

the pentabasic motif and Ser600 ranges between 4.6 Å and 17.8 Å. The difference between the
control and the pentabasic motif distances are significantly different (m=-22.05; p=<0.0001). JNK
and P38 are proposed to bind the PRRC motif and phosphorylate eNOS at Ser114. The distance
between the PRRC motif and Ser114 ranges between 18.5 Å and 23.7 Å. Again, the PRRC
distances compared to the control are significantly different (m=-13.42; p=0.0037). The
differences between the Pentabasic motif distances and the PRRC motif distances are calculated
to be significant (m=-8.633; p=0.0341).
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DISCUSSION
Taken together, the results help highlight the differences between the distances of where
MAP Kinases dock and phosphorylate eNOS. Because there are only three crystal structures of
NOS reductase domain (none of which are eNOS), designing a model of human eNOS reductase
domain was 1) necessary for measurements and calculations, and 2) allows insights to the
structural properties of eNOS. However, there are caveats that come with designing a model. The
majority of the heNOS reductase domain model is based on homology modeling (specifically, the
rat nNOS reductase domain (1TLL; 67). The AI insertion, which encompasses both the proposed
binding site at the KRRK motif and the Ser600 phosphorylation site, is based on ab initio modeling,
making its position uncertain. A partial a-helix from nNOS (67) superimposes over the AI insertion
of the model increasing our confidence in the model of the AI insertion.

The AI insertion is based not only on ab initio modeling but also on the overall fold of the
template protein. This also gives rise to uncertainty. For example, the distances between the
pentabasic motif and Ser600 may vary based on phosphorylation at Ser615 and Ser635.
Phosphorylation at one or both may repel parts of the AI insertion further or closer away from the
phosphorylation site. In addition, calmodulin binding near the AI insertion may move it from the
bulk of the reductase domain.

A

B

C

Figure 8: Measurement of the distances between kinases docking and phosphorylation sites
(A) Crystalized structure of Arrestin2 depicting the calculated distances between Lys400 and
Asp26 as a representative model. (B) Crystalized structure of bovine eNOS PRRC motif
depicting the calculated distances between Ser116/114 and Lys104 as a representative model. (C)
Model of heNOS depicting the calculated distances between Ser602/600 and Lys631 as a
representative model.
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The most likely cause for
the

big

differences

binding/phosphorylation

in

the
site

distances between Arrestin2 and
the other proposed MAP Kinases
recognition sequence is that the
sequence between 401 and 418,
which

includes

the

phosphorylation site, is not visible
in 2WTR (66). I used the visible
amino acid (Lys400) closest to the
docking site to estimate the
distance between the docking site
and the phosphorylation site.
Lys400 is thus 12 amino acids
away from the phosphorylation

Table 2: The distance measurements between kinases
docking sites and proposed phosphorylation site.
Amino Acid
Pentabasic
PRRC
B-Arrestin
Ser600-Arg627

4.6

Ser600-Arg628

11.2

Ser600-Lys629

12.7

Ser600-Arg630

14.2

Ser600-Lys631

17.8

Leu103-Ser114

23.7

Val104-Ser114

20.0

Leu105-Ser114

18.5

Lys400-Asp26

30.2

Lys400-Phe27

33.9

Lys400-Val28

35.0

Lys400-Asp29

37.5

Averages

12.1

20.7

34.15

site.
Although the bulk of the data in inclusive, it does appear that the distance between Ser600
and the pentabasic motif is within a distance that coincides with the PRRC motif. In the results,
there is a statistical difference between the distances of the PRRC and the pentabasic model.
However, because the model may have conformational discrepancies there is not enough evidence
to rule out the pentabasic or PRRC motifs as recognition sequences for MAP Kinases.
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Chapter 3: Understanding how MAP Kinases effect eNOS Activity through
Differential Phosphorylation

INTRODUCTION
Our lab previously published that ERK binds eNOS with high affinity (50). We followed
by publishing that ERK phosphorylates eNOS at Ser600 in a time dependent manner in vitro and
phosphorylation at Ser600 is a physiological occurrence (46). eNOS is heavily regulated through a
number of other PTM and depends on co-factors and substrates to be catalytically active. These
factors make eNOS a “difficult” protein to work with and purify. As discussed in chapter 1 eNOS
requires heme, BH4, and zinc to stabilize the oxygenase domain as well as FMN and FAD to
stabilize the reductase domain. Our eNOS is optimized for E. coli expression with a histidine tag
for affinity purification.
eNOS catalyzes the conversion of L-arginine, molecular oxygen, and NADPH to NO and
L-citrulline (see chapter 1). For this reaction to occur eNOS must contain high spin state heme (a
final electron acceptor); this species of heme only exists when eNOS is in the dimeric form and
when this occurs a Soret peak can be measured spectrophotometrically at 400nm. Originally,
bovine eNOS was expressed in a proteinase-deficient E. coli strain BL21-DE3 (Novagen) with
growing conditions optimized for the expression system; however, this expression regimen proved
to be difficult in our hands. Herein we present our results improving eNOS production; using an
optimized plasmid that expresses human His-tagged eNOS in E. coli. In addition to creating a new
plasmid, we have also optimized our protocol for eNOS purification and we are working with
human eNOS, which enables a better understanding of human regulatory issues.
Hemoglobin and the Measurement of Nitric-Oxide
The assay our lab uses to measure NO is the conversion of oxyhemoglobin to
methemoglobin (70). Hemoglobin is a globular protein comprised of four subunits containing
heme groups. The heme groups contain an iron (Fe) ion that coordinates with six sites, four of
which are nitrogen atoms. The fifth coordination site is covalently bonded with histidine and the
sixth coordination site determines the fate of the hemoglobin protein. Oxygen and other small
molecules bind Fe and affect the electron structure and magnetic properties of hemoglobin (71).
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Figure 9: Schematic representation of hemoglobin species and measurements in
oxyhemoglobin to methemoglobin.
Oxyhemoglobin can be measured at 421nm followed by two peaks at 532nm and 585nm
(A&C) while the methemoglobin peak absorbance is at 401nm (B&C). As NO is
synthesized oxyhemoglobin should be oxidized leading to less absorption at 421nm (D) and
increase in 401 (E). Absorbance at 421 can be subtracted from absorbance at 401nm (F).
When molecular oxygen binds the sixth site of hemoglobin, it is termed oxyhemoglobin
conversely, when hemoglobin is oxygen free it is considered to be deoxyhemoglobin. There are
partial species of hemoglobin that binds other small molecules such as NO; in this case, the
hemoglobin is termed methemoglobin. Because there is a spectrophotometric difference between
oxyhemoglobin and NO-bound hemoglobin (methemoglobin), we can measure NO synthesis
using the oxyhemoglobin to methemoglobin assay. When eNOS is incubated with oxyhemoglobin,
the NO that eNOS produces coverts oxyhemoglobin to methemoglobin as shown in figure 1. This
assay monitors the absorption difference between 401nm (oxyhemoglobin) and 421nm
(methemoglobin) or just at 401nm (Figure 9). Over the years this protocol has enabled eNOS
activity analysis in vitro and has been modified to enable NO detection in ex vivo experiments (72,
73).

Objective and Hypothesis
Our objective is to understand how MAP Kinases influence the ability of eNOS to generate
NO. As previously mentioned, ERK, P38, and JNK have all shown an ability to bind eNOS,
however, there is conflicting evidence on how these kinases influence eNOS synthesis of NO. This
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chapter aims to characterize how MAP Kinases phosphorylate eNOS and the influence that MAP
Kinases have over NO production.

EXPERIMENTAL PROCEDURES
Materials
Riboflavin 98%, Ampicillin, L-arginine, (6R)-5,6,7,8-tetrahydrobiopterin, bovine
calmodulin, human hemoglobin, flavin adenine dinucleotide disodium salt hydrate, NADPH
tetrasodium salt, acetylated-BSA, riboflavin 5′-monophosphate sodium salt hydrate, superoxide
dismutase bovine (Catalog #9054-89-1), and catalase from bovine liver (Catalog #C1345), were
all purchased from Sigma-Aldrich. Electrophoresis reagents, chambers, and tris-acetate 3-8% gels
were purchased from Bio-Rad. 5-Aminolevulinic acid was purchased from Cayman Chemical.
Terrific Broth, isopropyl-beta-D-thiogalactopyranoside, Tris-HCl, sodium chloride, imidazole,
tween20,

calcium

chloride,

4-(2-hydroxyethyl)-1-piperazineethanesulfonic

hydroxyethyl)-1-piperazineethanesulfonic

acid

(HEPES),

magnesium

acid,
chloride,

4-(2β-

glycerophosphate disodium salt, glycerol, and dithiothreitol were all purchased from Genesee
Scientific. Protease Arrest was purchased from G-Biosciences, and Slide-A-Lyzer Dialysis
Cassette were purchased from Thermofisher Scientific. Monoclonal antibody against NOS3 (250
µg/ml used at a 1:1000 dilution; Catalog#: 610297) was purchased from BD-Biosciences.
Phospho-specific S600 (0.9mg/mL used at a 1:500 dilution; ABS1631) eNOS antibody was made
in-house and can be purchased from Millipore Sigma. Phospho-specific Ser114 (1:500 dilution;
Lot# 2973090) eNOS antibody was also purchased from Millipore. Human Phospho-eNOS
(S1177) antibody was purchased from R&D Systems. cAMP-dependent Protein Kinase (PKA),
Catalytic Subunit (lot #P6000L) was purchased from New England Biolabs. GST-purified MAP
Kinases ERK (Lot #P1662-5) and JNK (Lot #X561-2) were purchased from SignalChem. Hispurified MAP Kinases ERK and P38 were made in house, as described previously (74).
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Methods
eNOS Purification
Table 3: Buffers used for the purification of eNOS
50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10%
Buffer
Glycerol, 6mM BME, 5-10ug, DNase I, 2x Protease Arrest,
G
Hi Control
100M BH4, 0.5% Tween 20, 5M FAD, 5M FMN
Strain
Buffer 50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10%
Purification
H
Glycerol, lmM BME, 5M FAD, 5M FMN
of eNOS
Buffer 50 mM Tris-HCl (pH-8.0), 500 mM NaCl, 10 mM Imidazole, 10%
I
Glycerol, lmM BME
Buffer 10mM Hepes (pH-7.4), 150mM NaCl, 0.05% Tween 20, 10%
Z
Glycerol, 1mM DTT
Desalt Buffer
eNOS Transformation and Inoculation
The polyHis-pet19b.eNOS vector (Ampicillin resistant) optimized for E. coli was designed
by Genewiz and verified in house by 5' NdeI and 3' XhoI restriction digest. After verification
pet19b.eNOS was transformed into Hi-Control competent cells transfected with chaperons CPN
10 and 60 from the Artic Express strains (Agilent technology), plated on ampicillin and gentamicin
containing plates for 13 hours and stored at 4º-8ºC up to 5 days. Single colonies were grown in
50mL cultures overnight at 37 ºC (220 rpm). The next day 13mL of the overnight solution was
used to inoculate 2.8 L Fernbach flask flasks each containing 1L of terrific broth (47g/L) and
supplemented with ampicillin (100 ug/mL final concentration), riboflavin (1.5 mg), and
aminolevulinic acid (167.6 mg). Flasks were placed in an orbital shaker and allowed to grow at
37ºC (220 rpm) in the dark. The OD600 was checked periodically during the growth period until it
reached an OD600 of 0.8–1.0 (4–5 h) then the cultures were supplemented with adenosine-50triphosphate (ATP, 100mg) and isopropyl-beta-D-thiogalactopyranoside (IPTG, 1 mM final
concentration, to induce the T7 promoter). The cells were incubated for 16–48 h at 23 ºC (220
rpm) again in the dark. Bacteria were harvested and pelleted by centrifugation using a FiberLite
F6 6 1000 rotor at 4ºC (7,000 rpm) for 10 min and stored in the -80 ºC
eNOS Expression and Purification
The pellets (typically 2) were thawed, immediately transferred into resuspension buffer G,
vortexed and resuspended at 4ºC, then lysed using a french press. The lysates were then centrifuged
at 4ºC (18,000 rpm) for 20min. The supernatants were incubated with 1mL of TALON cobalt resin
beads for 20-30 minutes using buffer G without the DNase, Lysozyme, Tween 20, and DNAse.
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The beads were washed with buffer H three times to wash away nonspecific proteins. Elution of
histidine-tagged protein was accomplished using buffer I and collected in 1mL fractions. A subset
of the elution was subjected to SDS-PAGE with Coomassie blue staining and/or immunoblotting
analysis. Fractions with higher protein concentrations (determined by crude pierce 600 nm protein
assay) were dialyzed overnight using a Slide-A-Lyzer dialysis cassette in buffer Z spiked with
1mM DTT. It is important to note all steps of the purification were performed at 4 ºC, and purified
eNOS was stored at -80ºC. Protein homogeneity was confirmed using SDS-PAGE with Coomassie
blue staining and western blot with anti-eNOS antibody at a 1:1000 dilution. The final protein
concentrations were measured in each fraction by total protein (pierce 660nm assay; (75))
concentration and by heme concentration. Concentrations of heme-containing eNOS were
determined from the absorption spectrum of the protein using the extinction coefficient E400 nm
=100 mM-1 cm-1 for the ferric enzyme (70).
eNOS Binding
Biolayer Interferometry (BLI) experiments were performed using a FortéBio (Menlo Park,
CA, USA) Octet QK using streptavidin sensors. Assays were done in black 96-well plates at 25°C;
200M volumes were used in each well. Biotinylated Tat-CaM (provided by the McMurry lab
(50)) in a 1M solution was loaded onto sensors for 300s followed by baseline measurements in
NEB binding buffer (pH 7.4; 10mM Hepes, 0.15M NaCl, 100mM CaCl2, 10% Glycerol and 1mM
DTT) for 300s. Association was measured by dipping sensors into solutions of purified eNOS
sample diluted to final concentrations of 31.5nM-2M using NEB buffer and was followed by
moving sensors to 0.5mM EDTA buffer to monitor dissociation.
Kinase Assays
Kinase reactions were performed in 20 mM HEPES (pH 7.4 at RT), 0.5 mM DTT, 5 mM
MgCl2, 0.5 mM ATP, and 10% glycerol. eNOS was used at various concentrations reported in the
figure legends. Reactions were incubated for up to 60 minutes with various concentrations of
kinases (also reported in figure legends) at 22-25 ºC. The reactions were quenched in 1x sample
buffer spiked with 25mM DTT and boiled for 5 minutes unless otherwise stated. Samples were
electrophoresed by equal volume (indicative of equal protein) western blotted and probed with
either anti-eNOS (Bb-Biosciences) at a 1:1000 dilution, eNOS phospho-specific S600 (described
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previously (46)) at a 1:500 dilution, or eNOS phospho-specific S114 (Millipore) at a 1:500
dilution.
Western-Blotting and Detection
Either 3-8% gradient tris-acetate gels (76) or 10% SDS-page gels were loaded with 30L
(1.71g) or 20L (1.14g) volume respectively. Gels were transferred to PVDF membranes and
transferred for either 2 hours (Tris-acetate) at 40V or for 1 hour at 100V (SDS-page) at RT.
Samples were blocked with one block (77) for 30 minutes and incubated with either Phosphospecific antibodies pSer114 or pSer600 at 4ºC for no less than 14 hour or non phospho antibodies
anti-eNOS for 2-4 hours at room temperature. The next day the blots were brought to RT for at
least 30 minutes before being washed with 1X TBST for 10 minutes (3x) and then probed with
fluorometric secondary antibody (Li-Cor IRDye®) for 45-60 minutes. The blots were washed again
in TBST as described before and then visualized with a Li-Cor Odyssey.
Nitric-Oxide Synthesis Measurement
Kinase assay reactions were performed as described above and quenched on ice until ready
to proceed (typically not more than 10 minutes). NO synthesis was measured using the
spectrophotometric oxyhemoglobin to methemoglobin assay. The assays were performed at 25 °C
in a BioTek 96-well UV-visible spectrophotometer. eNOS was assayed at concentrations depicted
in figure legends, in a 100-μl total volume per well. Unless otherwise stated, the final
concentrations of the assay constituents were 1μM FAD, 1μM FMN, 10% glycerol, 12nM BH4
(stock BH4 was made with oxygen free water and stored with 30 mM dithiothreitol), 100 μM Larginine, 10 mM Tris-HCl, pH 7.5 at 25°, 250μM CaCl2, 0.20 mg/ml BSA, 0.31mg Hemoglobin,
7-10U Superoxide Dismutase, 7-10U Catalase, and 17μg CaM (78). The reaction was initiated by
addition of 200M NADPH reconstituted in Tris-HCl (1.4M pH 7.5RT). OD was read at 401nm,
421nm, and 340nm. Prior to the addition of NADPH, kinetic readings were taken for 1 minute at
15 second intervals. The NADPH was then added and kinetics readings were taken for 10 min at
15 second intervals.
eNOS Activity Calculation
To calculate eNOS activity the change in absorbance/unit time was divided by the
extinction coefficient (77,200 M-1 cm-1 for 401nm-421nm or 38,600 M-1 cm-1 for 401nm alone).
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This yielded eNOS activity in units of molar change/unit time. The value was then multiplied by
the final reaction mixture volume and divided by the weight of the protein in that volume and
multiplied by 4. This gave a final eNOS activity of moles/unit time per weight of total protein (70).
𝑒𝑁𝑂𝑆 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =

𝑠𝑙𝑜𝑝𝑒
min 60
4
∗ 100𝑥10−6 ∗
∗
−9
𝑒𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡
1𝑥10 𝑛 𝑀𝑜𝑙 𝑚𝑔 𝑒𝑁𝑂𝑆

RESULTS
Purifying Active eNOS
Pet19b was used to express catalytically active human recombinant eNOS in Hi Control
strains co-transformed with chaperons CPN 10 and CPN 60 using the T7 promoter. The cells were
induced by IPTG and the crude supernatants were purified over TALON Cobalt resin. The desalted
elutions showed a visible band with a molecular mass of 150 kDa via Coomassie Blue-stained
SDS gels (Figure 10.A). The spectra of purified ferric eNOS was desalted and spiked with 2mM
BH4 shown in figure 10.B. A Soret peak can be found above 400nm and shifts to the right in less
concentrated eNOS fractions. Biolayer interferometry binding data shows that eNOS binds
calmodulin with high affinity as evinced between 630sec-930sec, stays tightly bound in the
presence of buffer (930sec-1230sec), and only dissociates in an EDTA buffer solution (1230sec1530sec) as shown in figure 10.C.
eNOS is Differentially Phosphorylated in vitro
Figure 11 depicts time dependent eNOS phosphorylation via western blotting with
pSer600, pSer114, and anti-eNOS antibodies. eNOS (3.3M) was incubated independently with
different MAP Kinases, either ERK (15M), JNK (28M), or P38 (5.7M) for up to 60 minutes
and quenched as mentioned previously. The reactions were loaded onto a 3-8% Tris-acetate gel.
The results (Figure 11.A) displayed differential phosphorylation in a time-dependent manner. ERK
showed preferential phosphorylation at Ser600 while JNK preferentially phosphorylated eNOS at
Ser114; P38 phosphorylated both sites. This experiment was performed in triplicate using an
enzymatic ratio (based on activity) of kinase to eNOS. Figure 11.B shows 3M eNOS incubated
with 1.2M JNK, 1.2M ERK, or 7M P38 independently. Again, ERK showed preferential
phosphorylation at Ser600 while JNK preferentially phosphorylated eNOS at Ser114; P38
phosphorylated both sites.
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eNOS activity changes are different between the MAP kinases
The activity of eNOS after pre-incubation with active MAP kinases was calculated at both
401nm and at 410nm-421nm. eNOS (3.3uM) was incubated with 1.2M ERK and JNK for 30 and
50 minutes and quenched on ice.
After a 30 minute kinase assay with
JNK, eNOS activity showed a 31%
(N=3) decrease in activity at 401nm
as compared to a 33.8% (N=5)
decrease in eNOS incubated with
ERK; highlighted in figure 12.A.
After 50 minutes, figure 12.C
shows there was no significant
change in eNOS activity when
incubated with JNK (N=4) while
ERK incubation decreased eNOS
activity by 85% (N=4; p=0.0168)
measured at 401nm. eNOS activity
measured by 401nm-421nm after a
30 minute kinase assay resulted in a
33.5% (N=5) decrease in activity
after ERK incubation and a JNK did

Figure 10: Purified eNOS absorbance spectrum from
Hi Control cells co-transformed with chaperones CPN
10&60 and eNOS.

not significantly impact eNOS
activity as there was a 14% (N=3)
decrease in activity; shown in figure
12.C. However, after 50 minutes
eNOS activity was not significantly
altered (Figure 12.D) by JNK or

(A) SDS-PAGE gel stained with commassie brilliant
blue reagent. Loading order: Marker Lane 1, Elutions 1
and 2 are lanes 2 and 3 respectively. (B) Absorption
spectrum of his-tagged elutions 1-3. (C) Biolayer
interferometry data displaying eNOS (31.5nM-2uM)
binding to biotinylated Tat-CaM for 300 seconds,
remaining bound when incubated with buffer and
finally dissociated with 0.5mM EDTA buffer.

ERK (N=4).
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eNOS activity is not inhibited by ERK in different conditions
ERK and P38 (Figure
13) do not

inhibit eNOS

activity. ERK was purified in

A

house without the presence
glutathione

(GSH)

and

incubated with eNOS. PKA
incubation with eNOS (Figure
13.a; N=4) served as a positive
control for the assay showing a
78% increase in eNOS activity.
ERK

treated

eNOS

(N=3)

shows a 28% non-significant

B

activation of eNOS activity
(Figure

13.B),

while

P38

treated eNOS (N=3) shows
11.5% non-significant increase
in eNOS activity after a 30
minute incubation with eNOS
(Figure 13.c).
DISCUSSION
A years’ worth of work
went into learning how to
purify

active

eNOS.

Figure 11: MAP Kinase differently phosphorylates eNOS
Western blot of eNOS incubated with JNK, P38, ERK for
5 & 60min, sample buffer. Immunoblotted for phosphospecific antibodies Ser600/602 and Ser114/116 (Millipore).
Loading Control is anti-eNOS (BD-Biosciences). (A)
eNOS incubated with excess amount of kinase and (B)
eNOS incubated with an enzymatic ratio of kinase to
substrate. (Ser114/600 is human numbering and Ser116/
602 is bovine).

Throughout the process, there were setbacks in understanding what factors are necessary for eNOS
stabilization. This difficult process was necessary and shows the complexity behind eNOS folding
and stabilization. BDP BL21 cells were first used for eNOS purifications, and while these cells
bountifully expressed eNOS there was no heme incorporated into the protein. Our interpretation
is that the precursor δ-aminolevulinic acid is rendered useless in the presence of blue light (hence
the requirement for the dark) frequencies. When eNOS was expressed in the dark we saw a change
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in

pellet

color

(dark

brownish-reddish

appearance) and a heme Soret peak at
approximately 415nm to 420nm.
Next, a variety of expression systems
were tested and the best outcomes were found
using hi-control cells in the dark with the artic
express chaperones; this system has enabled
the production of full length eNOS. This will
allow our lab to study the population of eNOS
that exists as a dimer versus the amount that
exists as a monomer from a purification. We
hypothesize that the monomer population is
misfolded and cannot form a dimer to produce
NO. We saw these characteristics in the eNOS
that was purified from other strains. We
hypothesize that the majority of the eNOS
from the purification existed as a monomer
and through heme was bound eNOS could not
form a dimer to produce NO because of
A

Figure 12: ERK inhibits eNOS activity while
JNK does not.
(A-D) In the presence of GSH, ERK negatively
impacts eNOS ability to produce NO (as
mentioned in text) while JNK does not. 3.3uM
eNOS was incubated independently with either
7.5nM JNK or 1.2nM ERK for 30 or 50
minutes. Absorbance at either 401nm (A&B)
or 401nm-421nm (C&D) was used to calculate
activity.

B

C

Figure 13: ERK and P38 do not significantly alter the activity of eNOS.
(A-C) 1.2M PKA, 1.2M ERK, and 3M P38 were incubated with 3.3uM eNOS for 30
minutes. Absorbance at 401nm-421nm was used to calculate activity.
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misfolding. Nevertheless, we did succeed in purifying active dimeric eNOS that we can currently
use for activity experiments.
Our active eNOS allowed the above experiments to explore the manner in which MAP
kinases interact with eNOS. Our previous data originally showed that ERK binds eNOS (50)
building on data from the Michel lab (53) that showed ERK was interacting with eNOS in cells.
The following year we published that ERK phosphorylates eNOS at Ser600 in a time dependent
manner and showed that phosphorylation at Ser600 is present in cells. We now present that P38 and
JNK phosphorylate eNOS in addition to ERK and that they do so in a differential way. This
supports our original Mass Spectrometry data that did not find eNOS to be phosphorylated at Ser114
by ERK (46). Originally, we exceeded the enzymatic ratio of kinase to substrate to ensure that
eNOS phosphorylation was occurring in vitro as shown in figure 11.A. We then backed down to
an enzymatic ratio of kinase to substrate based on calculated activity and still, results show eNOS
phosphorylation by MAP kinases results in different residues being preferentially targeted in figure
11.B.
Once we realized that MAP Kinases differentially phosphorylate eNOS we hypothesized
that MAP Kinases might differentially alter eNOS activity. However, when we originally tested
MAP Kinases ability to modulate eNOS activity the data was inconclusive. Measurement at 401nm
is designed to exclusively measure the formation of methemoglobin by NO. However, when we
compared the 401nm data alone to the 401nm-421nm data there was a number of inconsistencies.
Those inconsistencies suggested that oxyhemoglobin is oxidized overtime but not by NO. When
we first started refining the protocol for measuring 401nm-421nm we could not understand how
under the same conditions the assay would give us inconsistent results. Originally, we assumed
that there was another species of hemoglobin that we could not spectrophotometrically test. At that
point, we tested adding SOD and Catalase to ensure that any superoxide formation would be
converted to water and prevent (lessen) interference with the assay. This appeared to work for a
while, however, we ran into another problem.
The critical issue of concern was that when our lab first did these assays they found that
ERK decreased eNOS activity up to 60% (46), which was unreproducible in our current hands.
However, there have been several changes – our source of eNOS is different and we are using
slightly different assays to obtain the data. However, with a change in the results, we needed to be
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very careful. We then began to reanalyze our data with calculating activity using 401nm
exclusively (as others have done previously (78)) and sure enough, we calculated a 40-80%
decrease in eNOS activity when incubated with ERK or JNK but not P38 and PKA. P38 incubation
with eNOS consistently shows no effect on altering eNOS activity throughout all experiments.
PKA incubation beforehand has also consistently produced enhanced NO synthesis. We then went
back to look at the storage buffer of the ERK and JNK from SignalChem and realized that the
buffer contains 10 mM glutathione (GSH). The kinases are GST-tagged and they do not desalt the
GSH from the buffer. GSH has shown to be a potent
inhibitor of eNOS in oxidative conditions via eNOS
glutathionylation at Cys689 and Cys908 and the
subsequent uncoupling of eNOS to produce
superoxide (79). Active P38 was produced in-house
and is His-tagged, one reason why P38 incubation
with eNOS might be different.
We are now purifying active ERK in-house.
When repeating the experiments with His-ERK and
His-P38, also purified in our lab we saw small nonstatistical increases in eNOS activity (figure 13). It is
possible that the changes in activity are due to other
interactions such as the binding of kinases
themselves

changing

activity

or

other

phosphorylation sites that are shared targets of ERK
and P38. For example figure 14 shows bovine eNOS
(1NSE 37) Oxygenase domain. If JNK were to bind
to the PRRC motif (green and blue), it could interfere

Figure 14: Bovine endothelial nitric-oxide
synthase
Depicts bovine oxygenase domain.
Heighted in Blue is the PRRC sequence
and specifically in green is a putative LVL
MAP Kinase recognition sequence. The
yellow highlight is the SP that JNK
phosphorylates. The blue box represents
the proposed JNK binding site and the red
circle is the catalytic domain contain
binding sites for heme, BH4, and Larginine.

with the flow of electrons to the heme center from the
pocket (red circle). Furthermore, JNK binding could impact the ability of L-arginine and BH4 to
freely flow through. Therefore, our continuing work aims to purify JNK in house and understand
how JNK modulates eNOS activity.
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Chapter 4: eNOS is Modified in Cells through Multiple Signaling Pathways

INTRODUCTION
eNOS is a cellular target of multiple signaling cascades. Our previous work showed that
eNOS is endogenously phosphorylated at Ser600 in bovine aortic endothelial cells (BAEC). At that
time, we did not try to manipulate levels of Ser600 in cells; since then, nothing we have treated cells
with has altered the level of Ser600 phosphorylation besides a pan cyclin dependent kinase (CDK)
and ERK1 inhibitor, which decreased levels. While these results with the inhibitor could strengthen
our argument that ERK endogenously phosphorylates eNOS in cells. The lack of change of cellular
status of Ser600 with known activators of ERK contradicts this interpretation. This provided an
exciting alternative about CDK as a physiologic Ser600 kinase, but our focus was on MAP kinases.
The hypothesis at the beginning of this work was that MAP Kinases P38, ERK, and JNK would
decrease eNOS activity through phosphorylation at Ser600 and/or Ser114. We hypothesized that in
cells there would be a population of eNOS phosphorylated at both activating and inhibitory sites,
creating “antagonistically phosphorylated” eNOS. However, our results necessitated a change in
our hypothesis. As presented in chapter 3 we found that in vitro MAP Kinases are not altering

Figure 15: Graphical representation of the dually phosphorylated eNOS hypothesis
PKA phosphorylates eNOS at Ser1177 increasing eNOS activity while we propose MAP Kinases
P38, JNK, and ERK phosphorylate eNOS at Ser600 or Ser114 and have no noticeable effect on
eNOS activity. However we question how phosphorylation at Ser1177 congruently with
phosphorylation at Ser600/Ser114 affects eNOS activity.
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eNOS activity. Therefore, we have reworked our hypothesis (Figure 15) to understand if there is a
subset of eNOS that can exist dually phosphorylated at Ser1177 and Ser600. It has been suggested
that protein kinase PKA phosphorylates both Ser1177 and Ser633 (55) and we observe in vitro that
ERK and P38 phosphorylate Ser600. Would phosphorylation concurrently at both sites lessen the
amount of NO produced, or enhance it? A number of studies show that perturbations of eNOS
phosphorylation are reported in a number of diseases and they emphasize its importance.
Furthermore, we understand that NO signaling is misregulated in disease models (6, 48, 80) and
that eNOS phosphorylation at Ser1177 helps to alleviate symptoms found in disease models (81).
However, we do not understand how and if a dually phosphorylated eNOS at Ser1177 and Ser600
has any physiological relevance. We postulate that this may be an endogenous mechanism to finetune NO production in cells for growth and proliferation.
Objective and Hypothesis
In the present study, we observe how ERK and pERK interact with eNOS under different
conditions in HMEC-1 cells. We also explore how phosphorylation at Ser600 happens concurrently
with activating site Ser1177, creating a subset of eNOS that is dually phosphorylated. These results
underscore the importance of MAPK interactions with eNOS showing that each MAPK creates a
unique phosphorylation pattern and probably a unique protein-protein interaction pattern.
MATERIALS AND METHODS
Materials
Human Microvascular Endothelial Cells (HMEC-1) were purchased from ATCC. The Lglutamine, trypsin, epidermal growth factor (EGF), and Fetal Bovine Serum (FBS) were purchased
from Atlanta Biologicals. The hydrocortisone, MCDB 131 media, DMEM low glucose media, and
insulin were purchased from Sigma Aldrich. Protein G Dynabeads were purchased from
Thermofisher Scientific. Monoclonal antibody against NOS3 (250 µg/ml at a 1:1000 dilution;
Catalog#: 610297) was purchased from BD-Biosciences. Phospho-specific Ser600 (0.9mg/mL at
a 1:500 dilution; ABS1631) eNOS antibody was made in-house and can be purchased from
Millipore Sigma. Phospho-specific Ser114 (1:500 dilution; Lot# 2973090) eNOS antibody was
also purchased from Millipore. Phospho-eNOS (Ser1177) (C9C3) Rabbit mAb #9570 antibody,
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (E10) Mouse mAb #9106 and p44/42 MAPK
(Erk1/2) Antibody #9102 were purchased from Cell Signaling Technology
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Human Microvascular Endothelium Cells (HMEC-1)
Frozen HMEC-1 cells were thawed, centrifuged at 1000RPM for 5 minutes (30°C) to
remove any storage DMSO, and resuspended into warm completed growth media (MCDB131
supplemented with 10% FBS, 1g/mL Hydrocortisone, 10mM Glutamine, 10ng/ml Epidermal
Growth Factor). Once the cells were 85-90% confluent, the cells were rinsed in trypsin (30sec)
and trypsinized (3mL for T75) for 3 to 5 minutes. Note that HMEC-1 cells strongly adhere to flask
surfaces. After the cells began to detach (as seen under a compound light microscope) they were
quenched with at 1:3 ratio (trypsin to full media) using full culture media and centrifuged at
1000RPM for 5 minutes (30°C). The old media was aspirated and the cell pellet was resuspended
with full media. Cells were plated at a 1:8 dilution and kept for up to 15 generations. Note, the lab
has changed this procedure, centrifugation is used for thawing cells, but in routine passages, as
directed by the ATCC the cells are just diluted to pass.
Harvest and Preparation of Cell Lysates
HMEC-1 cells are kept as previously described. In preparation for an experiment, in most
cases the cells were serum starved; old growth media was removed and replaced with DMEM low
glucose media for 3 to 4 hours prior to treatment. Cells were then treated with either 10ng/mL EGF
or 500nM insulin; see figure legends for details. After treatment, the cells were washed with cold
PBS, harvested (by scrapping) into pre-chilled lysis buffer (1% Igepal, 0.5% Triton-X-100, 1.5mM
MgCl2, 150mM NaCl, 50mM Tris (pH7.4 at 4°C), and 10 glycerol) supplemented with 1x protease
inhibitor (ThermoScientific #1861278), 1M micro-cysteine, and 2M sodium vanadate and
placed on ice for at least 15 minutes. The lysates were flash frozen in liquid nitrogen and stored 80°C.
Immunoprecipitation Assay
The lysates were thawed on ice, centrifuged at 12,000RPM (4°C) for 15 minutes, and the
supernatants were transferred to a fresh microcentrifuge tube. An aliquot of the lysate (280g) was
reacted with either 0.5g of pSer600 antibody or 0.7g of pSer1177 antibody for 30 minutes at
4°C, and then incubated with protein G- Dynabeads for an additional 45minutes. The samples were
eluted in 2x sample buffer spiked with 100mM DTT and boiled for 5-7 minute. The post-bind
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samples were subjected to sequential IP with anti eNOS antibody and eluted in the same manner.
The samples were analyzed via immunoblotting imaging.
RESULTS
ERK and not pERK bind eNOS in HMEC-1
HMEC-1 cells were seeded in 10cm plates and treated with 10ng/mL EGF for 5 and 10
minutes. They were harvested, lysed and split into two parts one was IPed with pSer600 the other
pSer1177 antibodies. The IP elutions were probed for either anti eNOS (top red), pSer1177 (top
green), ERK (bottom red), or pERK (bottom green) as shown in figure 16. The top left panel shows
that eNOS is dually phosphorylated even in the presence of EGF there is a population of eNOS
that is phosphorylated both at Ser1177
and Ser600. The top right panel shows
the loading control in green and that
there is a subset of eNOS that is
phosphorylated

at

Ser1177.

ERK

endogenously binds eNOS and when
treated with EGF for 5 or 10 minutes
the complex dissociates as shown in
the bottom panel to the left – the red

Figure 16: ERK binds differentially phosphorylated
eNOS.

doublet lacking pERK reactivity
completely. Furthermore, ERK does
not bind eNOS phosphorylated at

ERK binds eNOS after phosphorylation at Ser600,
whereas active ERK does not interact with Ser1177
phosphorylated eNOS or EGF treated cell.

Ser1177 and it appears that pERK does not co-immunoprecipitate with phosphorylated eNOS.
eNOS is phosphorylated through multiple signaling outputs in HMEC-1 cells
HMEC-1 cells were seeded in 15cm plates and treated with 500nM insulin for 60 minutes.
They were harvested, lysed and IPed with pSer600 and sequentially IPed with anti eNOS. The IP
samples were probed for either anti eNOS or pSer1177 as shown in figure 17. Cells treated with
and without insulin shows that eNOS is phosphorylated by multiple signaling inputs (EGF, insulin)
through phosphorylation at Ser600 and Ser1177. After the portion that had been IPed with pSer600
was removed the post bind was IPed with anti-eNOS and both IPs were probed with pSer1177.
This shows that there is a population of eNOS in cells that are not phosphorylated at Ser600 as
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shown in the top right panel of figure 8.
The bottom panel shows the loading
control and the lysate samples before the
IP is shown in the center.
DISCUSSION
Previous work from our lab
showed that eNOS phosphorylation at
600

Ser

is endogenous in primary BAEC

(46). This work takes a closer look into the
signaling inputs that regulate eNOS in
HMEC-1 cells. Our results show when we
treated cells with 10ng/mL EGF we saw
ERK

dissociate

from

eNOS;

we

hypothesize that EGF treatment leads to
increased phosphorylation of eNOS at

Figure 17: eNOS is phosphorylated through
multiple signaling outputs in HMEC-1 cells.
Immunoprecipitation analysis of modified eNOS
Ser1177 and Ser600. HMEC-1 cells at 80%
confluence were treated with 500nM Insulin for 60
min. The resulting lysates were sequentially
immunoprecipitated using anti-pSer600 followed
by anti-eNOS. Green panel shows anti-pSer1177
antibody staining; red shows anti-eNOS antibody
staining. (Ser114/600 is human numbering and
Ser116/602 is bovine).

Ser633 through increases in PKA activation and that displaces the ERK and/or prevents new
interactions. We have also shown from chapter 3 that ERK phosphorylates eNOS at Ser600 in
vitro and yet in ex situ experiments, we were not able to capture a pERK binding to eNOS. We are
not sure how to interpret that result however, one thought is the interaction between pERK and
eNOS is unstable and the environment that we lyse and IP cells with causes eNOS and pERK to
dissociate. Maybe a proximity ligation assay would help us gain more insights into this
phenomenon in situ.
The data from figure 8 also hints that there are different subsets of eNOS that have different
phosphorylation patterns. The lysates were first IP’ed with Ser600 and that captured dually
phosphorylated eNOS with Ser1177. However, the remaining post bind was sequentially IP’ed with
anti-eNOS showing that there is a subset of eNOS that is not phosphorylated at Ser600 and a subset
of eNOS that is not dually phosphorylated at both Ser600 and Ser1177. Characterizing the events that
lead to eNOS phosphorylation at Ser600 is a future step that is currently in progress will be
discussed a bit in chapter 5. However, figure 17 provides further evidence that eNOS is a target of
multiple-signal inputs, as has been suggested widely in the literature. The literature suggests that
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treatment with insulin promotes increase Ser1177 phosphorylation through the PKA or AKT and
we hypothesize that ERK promotes phosphorylation at Ser600. This may suggest cross talk between
these pathways and eNOS may be involved in some capacity. This research beings to highlight
eNOS in the center of multiple targets and may suggest eNOS has an important unknown role in
cells.
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Chapter 5: Conclusions, Future Directions, Integrative Statement, and
Acknowledgments
CONCLUSIONS & FUTURE DIRECTIONS
Our study has furthered our understanding of the complex modulation of eNOS.
Specifically, we have shown that MAP Kinases have distinct modes of interaction with eNOS and
have unique overlapping phosphorylation targets on eNOS. This began with successfully
designing and verifying a model of the human eNOS reductase domain to use in determining if
MAP Kinases can bind to the pentabasic motif within a distance that allows for subsequent
phosphorylation. Even though our data remains inconclusive, it did provide insights into the
interaction, allowing us to interpret that MAP Kinases bound to the pentabasic or PRRC motif
would enable phosphorylation at the Ser600 site or Ser114 site respectively. We hope to better
understand these interactions by characterizing the binding kinetics of MAP Kinase and the
predicted eNOS binding sequences. Specifically, we intend to design peptides of the autoinhibitory and PRRC motifs for in vitro analysis using biolayer interferometry. Also as future
directions, we aim to understand if there are any other known crystal structures of substrates
(known to bind MAP Kinases) to use as a control. Though MEK is upstream of ERK, MEK
phosphorylation capacity may be further than MAP Kinases ability to phosphorylate their
substrates. Therefore, having a MAP Kinases control could help us better understand the distances
from table 2.
The bioinformatics data was useful in understanding that MAP Kinases could have two
different sites of interaction supporting our data that shows that the kinases differentially
phosphorylate eNOS. It was our hypothesis that eNOS phosphorylation and subsequent
modulation in activity is dependent on where MAP Kinases bind. Our results show that MAP
Kinases differentially phosphorylate eNOS in vitro (Figure 11) however, understanding this
interaction in terms of activity proved more difficult for a number of reasons. MAP Kinases do not
alter eNOS activity, however much testing still needs to be completed on the topic. GSH was a
potential set back and as we work to remove GSH from all of our active kinases, our ability to
quantify each kinases specific activity proves difficult and is an aim for the future. What is slightly
confusing is that incubation of eNOS with these MAP kinases shows a consistent slight (nonstatistical) activation in activity. Another future aim is to determine if and how MAP Kinases
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binding eNOS may alter its activity specifically if MAP Kinases binding eNOS alter the flow of
electrons through the reductase domain.
While eNOS activity is not altered by MAP Kinases in vitro we do see evidence that
phosphorylation at Ser600 might be physiologically relevant. We have shown that eNOS is
phosphorylated by multiple signaling outputs in cells and have also shown that phosphorylation at
Ser600 happens congruently with phosphorylation at Ser1177. We have also shown that the MAP
Kinase ERK binds differently to phosphorylated vs. unphosphorylated eNOS. This shows that
eNOS might be at the center of a larger pathway and have another function from producing NO.
This MAP Kinase-eNOS interaction is an area of intense interest in the field. As an example, one
paper suggests that eNOS acts as a scaffold protein and hypothesizes that loss of eNOS contributes
more to inflammation than reducing the amount of NO eNOS can produce (82). This suggests
eNOS importance in cells exceeds the regulation of NO. However, as our last future aim, we do
want to characterize how dually phosphorylated eNOS impacts NO production. We want to
understand if phosphorylation at Ser600 after eNOS is already phosphorylated at Ser1177 causes a
dimmer-switch where the enzyme produces various outputs of NO depending on the varied
phosphorylation/other posttranslational modifications present. Taken together, we have presented
that MAP Kinases interact with and likely influence eNOS actions in cells and contributed to the
growing literature that eNOS is a highly regulated enzyme accepting various inputs to determine
how much NO to make and begin a signaling cascade anew.
INTEGRATIVE STATEMENT
The dysregulation of eNOS and NO production has been shown in a number of disease
modes such as T2DM, Alzheimer’s, Cardiovascular Disease, Inflammation, and more. Our
research could be implemented in a number of ways. By understanding how eNOS works and the
mechanism of NO production in cells will enable identification of pharmaceutical targets, more
translational studies and ultimately the initiation of clinical trials. Furthermore, this thesis
combines multiple techniques including bioinformatics/computational, analytical chemistry,
biochemistry, enzymology, statistics, cellular, organismal, and more, and utilizing this integration
has truly made me a better scientist. Finally, reactive oxygen species and reactive nitrogen species
are important in a number of areas of science, particularly environmental studies. Exposure to
industrial levels of nitrogen oxides can lead to death by collapse, burning, and swelling of
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respiratory tissues. In plants, exposure to high levels of nitrogen dioxide and monoxide is
dangerous. Furthermore, they contribute to acid rain formation which in turn damages vegetation
and water bodies. Understanding how nitrogen oxides work could possibly lead to different ways
to combat air pollution.
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SUPPLEMENTARY DATA
Table S1: NOS isolated from diverse species.
UniProt ID
Q28969
P70313
Q62600
P29473
P29474

Entry name
NOS3_PIG
NOS3_MOUSE
NOS3_RAT
NOS3_BOVIN
NOS3_HUMAN

Q9TUX8

NOS3_CANLF

P97270
P79209
A0A1D1YKK0
A0A1D1ZKN4

NOS3_CAVPO
NOS3_SHEEP
A0A1D1YKK0_9ARAE
A0A1D1ZKN4_9ARAE

Q80SZ9

Q80SZ9_SPECI

H9CZP9
V9ITD3

H9CZP9_CHICK
V9ITD3_CHICK

E8Z914

E8Z914_XENTR

H2QVM2

H2QVM2_PANTR

H0WJA4

H0WJA4_OTOGA

G1PQK0

G1PQK0_MYOLU

A0A1D5QGM1

A0A1D5QGM1_MACMU

G1M5X2

G1M5X2_AILME

H9GDL4

H9GDL4_ANOCA

A0A287DB04

A0A287DB04_ICTTR

A0A1U7RHA5

A0A1U7RHA5_MESAU

G3W5B1

G3W5B1_SARHA
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Organism
Sus scrofa (Pig)
Mus musculus (Mouse)
Rattus norvegicus (Rat)
Bos taurus (Bovine)
Homo sapiens (Human)
Canis lupus familiaris (Dog)
(Canis familiaris)
Cavia porcellus (Guinea pig)
Ovis aries (Sheep)
Anthurium amnicola (tulip)
Anthurium amnicola (tulip)
Citellus citellus (european ground
squril)
Gallus gallus (Chicken)
Gallus gallus (Chicken)
Xenopus tropicalis (Western
clawed frog) (Silurana tropicalis)
Pan troglodytes (Chimpanzee)
Otolemur garnettii (Small-eared
galago) (Garnett's greater
bushbaby)
Myotis lucifugus (Little brown
bat)
Macaca mulatta (Rhesus
macaque)
Ailuropoda melanoleuca (Giant
panda)
Anolis carolinensis (Green anole)
(American chameleon)
Ictidomys tridecemlineatus
(Thirteen-lined ground squirrel)
(Spermophilus tridecemlineatus)
Mesocricetus auratus (Golden
hamster)
Sarcophilus harrisii (Tasmanian
devil) (Sarcophilus laniarius)

Length
1205
1202
1202
1205
1203
1205
100
99
135
114
27
985
1146
1177
1203
1205
1,203
1,205
1,208
1,126
1,228
1,202
1,022

U6D6U1

U6D6U1_NEOVI

A0A1U7SJX6

A0A1U7SJX6_ALLSI

A0A093IGN2

A0A093IGN2_DRYPU

A0A0Q3MKC7

A0A0Q3MKC7_AMAAE

M7BX73

M7BX73_CHEMY

A0A2I0LJM0

A0A2I0LJM0_COLLI

V8NCF8

V8NCF8_OPHHA

A0A218UGU3

A0A218UGU3_9PASE

A0A1S3AL81

A0A1S3AL81_ERIEU

A0A2F0B4V9

A0A2F0B4V9_ESCRO

S9WKR6

S9WKR6_CAMFR

D7RVB4

D7RVB4_RABIT

M3WID9

M3WID9_FELCA

G1QV96

G1QV96_NOMLE

G3SZA3

G3SZA3_LOXAF

A0A0C4JN10

A0A0C4JN10_XENLA

P29475
Q9Z0J4
P29476
E1BKI3

NOS1_HUMAN
NOS1_MOUSE
NOS1_RAT
E1BKI3_BOVIN

J9P395

J9P395_CANLF

O19132

NOS1_RABIT

F1QVQ6

F1QVQ6_DANRE

E1C799

E1C799_CHICK

Neovison vison (American mink)
(Mustela vison)
Alligator sinensis (Chinese
alligator)
Dryobates pubescens (Downy
woodpecker) (Picoides
pubescens)
Amazona aestiva (Blue-fronted
Amazon parrot)
Chelonia mydas (Green sea-turtle)
(Chelonia agassizi)
Columba livia (Rock dove)
Ophiophagus hannah (King
cobra) (Naja hannah)
Lonchura striata domestica
(Bengalese finch)
Erinaceus europaeus (Western
European hedgehog)
Eschrichtius robustus (California
gray whale) (Eschrichtius
gibbosus)
Camelus ferus (Wild bactrian
camel) (Camelus bactrianus ferus)
Oryctolagus cuniculus (Rabbit)
Felis catus (Cat) (Felis silvestris
catus)
Nomascus leucogenys (Northern
white-cheeked gibbon)
(Hylobates leucogenys)
Loxodonta africana (African
elephant)
Xenopus laevis (African clawed
frog)
Homo sapiens (Human)
Mus musculus (Mouse)
Rattus norvegicus (Rat)
Bos taurus (Bovine)
Canis lupus familiaris (Dog)
(Canis familiaris)
Oryctolagus cuniculus (Rabbit)
Danio rerio (Zebrafish)
(Brachydanio rerio)
Gallus gallus (Chicken)
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506
886
882
838
534
507
721
843
1,012
379
936
1,209
1,202
1,128
1,199
147
1,434
1,429
1,429
1,325
1,465
1,435
1,429
1,435

H0X6T1

H0X6T1_OTOGA

H0ZJG3

H0ZJG3_TAEGU

G1PDA1

G1PDA1_MYOLU

G3W2Q3

G3W2Q3_SARHA

I3NFR7

I3NFR7_ICTTR

U3JXC0

U3JXC0_FICAL

U3IZ92

U3IZ92_ANAPL

F7BDV9

F7BDV9_XENTR

H9GND1

H9GND1_ANOCA

F7GBZ4

F7GBZ4_MONDO

M3XUN6

M3XUN6_MUSPF

K7FGK0

K7FGK0_PELSI

G1TUL9

G1TUL9_RABIT

Q7T3R9

Q7T3R9_TAKRU

I3JWS0

I3JWS0_ORENI

H2L651

H2L651_ORYLA

I3NF66

I3NF66_ICTTR

Otolemur garnettii (Small-eared
galago) (Garnett's greater
bushbaby)
Taeniopygia guttata (Zebra finch)
(Poephila guttata)
Myotis lucifugus (Little brown
bat)
Sarcophilus harrisii (Tasmanian
devil) (Sarcophilus laniarius)
Ictidomys tridecemlineatus
(Thirteen-lined ground squirrel)
(Spermophilus tridecemlineatus)
Ficedula albicollis (Collared
flycatcher) (Muscicapa albicollis)
Anas platyrhynchos (Mallard)
(Anas boschas)
Xenopus tropicalis (Western
clawed frog) (Silurana tropicalis)
Anolis carolinensis (Green anole)
(American chameleon)
Monodelphis domestica (Gray
short-tailed opossum)
Mustela putorius furo (European
domestic ferret) (Mustela furo)
Pongo abelii (Sumatran
orangutan) (Pongo pygmaeus
abelii)
Gorilla gorilla gorilla (Western
lowland gorilla)
Takifugu rubripes (Japanese
pufferfish) (Fugu rubripes)
Oreochromis niloticus (Nile
tilapia) (Tilapia nilotica)
Oryzias latipes (Japanese rice
fish) (Japanese killifish)
Ictidomys tridecemlineatus
(Thirteen-lined ground squirrel)
(Spermophilus tridecemlineatus)
Scleropages formosus (Asian
bonytongue)
Salmo salar (Atlantic salmon)
Nothobranchius furzeri
(Turquoise killifish)
Stylophora pistillata (Smooth
cauliflower coral)

A0A1W4YWX6 A0A1W4YWX6_9TELE
A0A1S3NJT5

A0A1S3NJT5_SALSA

A0A1A8U6L9

A0A1A8U6L9_NOTFU

A0A2B4RPN3

A0A2B4RPN3_STYPI
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1,434
1,417
1,433
1,152
1,329
1,435
1,431
1,427
1,457
1,468
1,467
1,437
1,468
1,418
1,428
1,423
1,287
1,420
1,269
1,418
1,155

C3UNG7

C3UNG7_9CRUS

Daphnia magna

1,182

P35228
P29477
Q06518
Q90703
O54705
F1MYR5
Q28314
Q92037

NOS2_HUMAN
NOS2_MOUSE
NOS2_RAT
NOS2_CHICK
NOS2_CAVPO
F1MYR5_BOVIN
NOS2_CAPHI
NOS2_CARAU

1,153
1,144
1,147
1,136
1,149
1,156
110
164

A0A2D0SXG4

A0A2D0SXG4_ICTPU

F7FZ21

F7FZ21_MONDO

G3UET8

G3UET8_LOXAF

H2NT20

H2NT20_PONAB

U3JQR4

U3JQR4_FICAL

H0ZEC8

H0ZEC8_TAEGU

G1LF17

G1LF17_AILME

K7G898

K7G898_PELSI

G3W4E3

G3W4E3_SARHA

M3YSE6

M3YSE6_MUSPF

U3J9H8

U3J9H8_ANAPL

F6SZU1

F6SZU1_MACMU

A0A287BRU8

A0A287BRU8_PIG

G3UTC3

G3UTC3_MELGA

F6W1L2

F6W1L2_XENTR

H9GMP6

H9GMP6_ANOCA

A7WK81

A7WK81_DANRE

Homo sapiens (Human)
Mus musculus (Mouse)
Rattus norvegicus (Rat)
Gallus gallus (Chicken)
Cavia porcellus (Guinea pig)
Bos taurus (Bovine)
Capra hircus (Goat)
Carassius auratus (Goldfish)
Ictalurus punctatus (Channel
catfish) (Silurus punctatus)
Monodelphis domestica (Gray
short-tailed opossum)
Loxodonta africana (African
elephant)
Pongo abelii (Sumatran
orangutan) (Pongo pygmaeus
abelii)
Ficedula albicollis (Collared
flycatcher) (Muscicapa albicollis)
Taeniopygia guttata (Zebra finch)
(Poephila guttata)
Ailuropoda melanoleuca (Giant
panda)
Pelodiscus sinensis (Chinese
softshell turtle) (Trionyx sinensis)
Sarcophilus harrisii (Tasmanian
devil) (Sarcophilus laniarius)
Mustela putorius furo (European
domestic ferret) (Mustela furo)
Anas platyrhynchos (Mallard)
(Anas boschas)
Macaca mulatta (Rhesus
macaque)
Sus scrofa (Pig)
Meleagris gallopavo (Wild
turkey)
Xenopus tropicalis (Western
clawed frog) (Silurana tropicalis)
Anolis carolinensis (Green anole)
(American chameleon)
Danio rerio (Zebrafish)
(Brachydanio rerio)
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1,080
1,139
1,155
1,153
1,147
1,117
1,158
1,092
1,153
1,064
1,150
1,112
1,195
1,138
1,109
1,327
1,079

Q1KYT1

Q1KYT1_MESAU

F6PYQ6

F6PYQ6_HORSE

F6QRL0

F6QRL0_ORNAN

Q8AXU2

Q8AXU2_ONCMY

A0A1S3T1I3
A0A1X0QFB2

A0A1S3T1I3_SALSA
A0A1X0QFB2_9MICR

T2MFR4

T2MFR4_HYDVU

Q4PLU2

Q4PLU2_NEMVE

Q670V8

Q670V8_PODCA

Mesocricetus auratus (Golden
hamster)
Equus caballus (Horse)
Ornithorhynchus anatinus
(Duckbill platypus)
Oncorhynchus mykiss (Rainbow
trout) (Salmo gairdneri)
Salmo salar (Atlantic salmon)
Hepatospora eriocheir
Hydra vulgaris (Hydra) (Hydra
attenuata)
Nematostella vectensis (Starlet
sea anemone)
Podocoryna carnea (Hydrozoan)
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1,150
1,097
1,144
1,083
1,083
356
1,066
256
333

